Zelira Therapeutics Ltd has released a press release.
Preliminary Final Report
Filed with ASX ·
6ix hasn’t read this filing yet.
Zelira Therapeutics Ltd. on 6ix
Earlier from Zelira Therapeutics
- Zelira Therapeutics Secures R&D Loan Facility
- Publication of ZLT-L-007 IRB Approved Observational Study
- Zelira secures $1 Million At-the-Market Funding Facility
- Appendix 4D & FY25 Interim Financial Report
- Zelira receives $1,153,000 R&D Tax Incentive Scheme Refund
Later from Zelira Therapeutics
- Zelira receives $1,070,000 R&D Tax Incentive Scheme Refund
- Transformative US$33M Fundraising into Zeliras HOPE 1 SPV
- Quarterly Activities/Appendix 4C Cash Flow Report
- Suspension from Quotation
- Long Term Suspended Entities
Follow Zelira Therapeutics into a list and get an email when it puts out news.
Follow Zelira Therapeutics